上海市中医药研究院关节病研究所

【概况】

上海中医药大学、上海市中医药研究院关节病研究所于2013年8月依托上海市光华中西医结合医院而建，由中国中医科学院首席研究员、香港浸会大学中医药学院院长吕爱平教授担任所长，2020年6月完成研究所领导班子换届改选，由光华医院院长肖涟波教授、副院长何东仪教授分别担任所长、副所长，形成院所合一的管理模式。研究所下设有尪痹中西医结合临床研究室、中西医结合骨伤研究室和中心实验室。中心实验室提供分子生物学、细胞学、临床免疫学、分子病理学等基础研究实验平台和生物样本库，紧紧围绕类风湿关节炎、骨关节炎、强直性脊柱炎、痛风等优势病种，以解决临床问题为导向，将关节病的中西医结合临床研究与分子生物学、细胞学、分子病理学、免疫学、关节功能研究、生信分析技术等现代技术相结合，强化基础与临床医学研究互为转化的能力，推进研究资源配置优化、多学科协同机制创新、样本库信息共享、关节病科研、教学人才队伍培养，实现医院完整的临床-科研-教学-转化一体化的发展平台。

研究所现有专职研究人员与博士后共11名，临床兼职研究人员27名，硕博士占比95%。依托医院临床优势，开展针、推、药在关节手术围手术期快速康复的应用研究；中药在防治骨破坏中的作用机制研究；自身免疫性疾病的早期辨证、精准治疗药物组合研究；风湿免疫病的中西医结合精准治疗临床诊疗方案的转化研究；疑难慢病大队列研究等。研究所通过PI合作制，与香港浸会大学生物信息与转化医学研究所、上海免疫学研究所、上海免疫与感染研究所、上海药物所、上海仁济医院、上海龙华医院、四川大学华西医院、暨南大学、广西医科大学数字医学与健康广西高校工程研究中心等单位均建立了良好的合作关系，不断在临床、基础转化方向进行新的探索和尝试。

以研究所为单位，共获得科研项目立项193项，项目经费达3227.92万元，其中国家级项目13项，省部级项目30项，局级项目95项；获得人才培养项目立项93项；发表论文531篇；主编著作10部，参编30部；发明专利授权2项，实用新型专利授权37项；牵头或参与制定国内指南或专家共识25部。自制制剂蠲痹强骨颗粒、芪蓝颗粒、愈伤通腑颗粒获得上海药品监督管理局备案许可，并正式进入临床使用。

【联系方式】

地址：上海市延安西路1508号

电话：021-62805833 分机：3013

E-mail: ghyjs_3013@126.com

The Institute for Joint Diseases

Our responsibilities

The Institute was founded in August, 2013. Our major responsibilities are as follows:

1.Focuse on addressing clinical challenges associated with dominant joint diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and gout.

2.Integrate clinical research on joint diseases with modern technologies,including molecular pathology, immunology, joint function analysis, and bioinformatics.

3.Strengthen the bidirectional translational capability between basic and clinical medical research.

4.Establish a hospital-wide integrated development platform that synergizes clinical practice, scientific research, education, and translational medicine.

Our achievements

By the end of 2024, the institute has secured 193 research projects with total funding of 32.28 million, including 13 national-level, 30 provincial/ministerial-level, and 95 bureau-level grants. It has trained researchers through 93 talent development programs and published 531 papers . Additionally, the institute has edited 10 academic books, contributed to 30 publications, and obtained 2 invention patents and 37 utility model patents. It has also led or participated in formulating 25 domestic clinical guidelines or expert consensuses. Notably, institutional pharmaceutical preparations such as Juanbi Qianggu Granules, Qilan Granules, and Yushang Tongfu Granules have been approved by the Shanghai Drug Administration for clinical use.

Our ongoing activities

1.Perioperative rapid rehabilitation techniques (acupuncture, manual therapy, and herbal medicine) for joint surgery;  

2.Mechanisms of traditional Chinese medicine in preventing and treating bone destruction;  

3.Early syndrome differentiation and precision drug combinations for autoimmune diseases;  

4.Translational studies on integrated traditional Chinese and Western medicine protocols for rheumatic and immune diseases;  

5.Large-cohort studies on refractory and chronic conditions.

Our staff

Professor Lu Aiping, Chief Researcher at the China Academy of Chinese Medical Sciences and former Dean of the School of Traditional Chinese Medicine at Hong Kong Baptist University, served as the institute’s inaugural director. In June 2020, the leadership was restructured, with Professor Xiao Lianbo (President of Guanghua Hospital) appointed as Director and Professor He Dongyi (Vice President) as Deputy Director, establishing an integrated management model between the institute and the hospital. The institute employs 11 full-time researchers and postdoctoral fellows, alongside 27 part-time clinical researchers, with 95% holding master’s or doctoral degrees.

Contact Us

Telephone: 021-62805833 Ext. 3013

Fax: 021-62809946

E-mail: ghyjs_3013@126.com

Address: 1508 West Yan’an Road, Shanghai